Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

Clinical trial NCT05286320 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05286320
Sponsor: National Taiwan University Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Unresectable Hepatocellular Carcinoma Pembrolizumab Lenvatinib Stereotactic Body Radiotherapy

Start date: 2023-03-01
Primary completion: 2026-09-30
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.